Drug Profile
Small molecule therapeutic - Nivarta
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Nivarta
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetes mellitus
Most Recent Events
- 13 Sep 2023 Early research in Diabetes mellitus is ongoing in the US (Nivarta pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 03 Aug 2016 Early research in Diabetes mellitus in USA (unspecified route)